Arcutis Biotherapeutics (ARQT) News Today → 41 banks launch ‘crypto dollar’ (From Stansberry Research) (Ad) Free ARQT Stock Alerts $9.20 +0.08 (+0.88%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 5:38 AM | americanbankingnews.comNeedham & Company LLC Increases Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00May 17 at 4:38 AM | americanbankingnews.comMizuho Increases Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00May 16, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.8%Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.8%May 16, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Significant Increase in Short InterestArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 21,690,000 shares, a growth of 10.3% from the April 15th total of 19,660,000 shares. Based on an average daily volume of 3,810,000 shares, the short-interest ratio is currently 5.7 days.May 16, 2024 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up After Strong EarningsMay 15, 2024 | markets.businessinsider.comUpgraded Buy Rating and Price Target for Arcutis Biotherapeutics Amid Zoryve’s Robust Sales PerformanceMay 15, 2024 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comQ1 2024 Arcutis Biotherapeutics Inc Earnings CallMay 15, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Announces Earnings Results, Beats Estimates By $0.28 EPSArcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.28. Arcutis Biotherapeutics had a negative net margin of 439.79% and a negative return on equity of 294.85%. The company had revenue of $49.57 million during the quarter. During the same period in the prior year, the firm posted ($1.31) earnings per share.May 15, 2024 | marketbeat.comNeedham & Company LLC Raises Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00Needham & Company LLC raised their target price on Arcutis Biotherapeutics from $16.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday.May 15, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up on Analyst UpgradeArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up Following Analyst UpgradeMay 15, 2024 | markets.businessinsider.comA Balanced Outlook: Maintaining Hold on Arcutis Amidst Zoryve’s Mixed Performance and Potential Growth CatalystsMay 15, 2024 | finance.yahoo.comArcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 14, 2024 | msn.comArcutis Biotherapeutics Stock Climbs After Blockbuster Q1 ResultsMay 14, 2024 | investorplace.comARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | markets.businessinsider.comArcutis Biotherapeutics: Strong Prescription Growth Fuels Buy RatingMay 14, 2024 | globenewswire.comArcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | msn.comArcutis Biotherapeutics Q1 2024 Earnings PreviewMay 13, 2024 | globenewswire.comExpert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DermatologyMay 12, 2024 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 5.4%May 12, 2024 | americanbankingnews.comArcutis Biotherapeutics (ARQT) to Release Earnings on TuesdayMay 11, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases Shares of 194,461 Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Los Angeles Capital Management LLC purchased a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 194,461 shMay 10, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.4%Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 5.4%May 7, 2024 | marketbeat.comArcutis Biotherapeutics (ARQT) Set to Announce Earnings on TuesdayArcutis Biotherapeutics (NASDAQ:ARQT) will be releasing earnings after the market closes on Tuesday, May 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591309)May 4, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.7% Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 6.7%May 3, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.9%Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.9%May 1, 2024 | marketbeat.comabrdn plc Acquires New Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)abrdn plc bought a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 148,874 shares of the company's stock, valued atApril 30, 2024 | marketbeat.comFederated Hermes Inc. Buys 461,469 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Federated Hermes Inc. lifted its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 769.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 521,469 shares of the company's stock aApril 29, 2024 | globenewswire.comArcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024April 26, 2024 | marketbeat.comArcutis Biotherapeutics Sees Unusually High Options Volume (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the target of unusually large options trading on Friday. Stock investors purchased 5,056 call options on the stock. This is an increase of 79% compared to the typical daily volume of 2,821 call options.April 26, 2024 | finance.yahoo.comIndustry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue ForecastsApril 25, 2024 | marketbeat.comJennison Associates LLC Purchases 4,633,907 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Jennison Associates LLC lifted its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 104.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,066,082 shares of the company'April 22, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)April 18, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.2%Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.2%April 16, 2024 | marketbeat.comDekaBank Deutsche Girozentrale Invests $462,000 in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)DekaBank Deutsche Girozentrale bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 140,000 shares of the company's stock, valued at approximatelApril 13, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest UpdateArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 19,260,000 shares, a growth of 28.5% from the March 15th total of 14,990,000 shares. Based on an average daily trading volume, of 4,760,000 shares, the days-to-cover ratio is currently 4.0 days.April 12, 2024 | morningstar.comArcutis Biotherapeutics Inc Ordinary Shares ARQTApril 12, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 8.8%Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 8.8%April 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)April 12, 2024 | markets.businessinsider.comEvaluating Arcutis Biotherapeutics: Insights From 5 Financial AnalystsApril 12, 2024 | marketbeat.comArcutis Biotherapeutics' (ARQT) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $16.00 price objective on shares of Arcutis Biotherapeutics in a report on Friday.April 10, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial OfficerApril 10, 2024 | markets.businessinsider.comArcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFOApril 10, 2024 | marketbeat.comTraders Buy Large Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors purchased 15,306 call options on the stock. This is an increase of 522% compared to the average daily volume of 2,461 call options.April 10, 2024 | marketwatch.comArcutis Biotherapeutics Names David Topper as Finance ChiefApril 10, 2024 | markets.businessinsider.comBuy Rating on Arcutis Biotherapeutics Bolstered by Projected Q1 Sales Beat and 2024 Upside PotentialApril 10, 2024 | msn.comArcutis Biotherapeutics appoints CFOApril 10, 2024 | globenewswire.comArcutis Appoints David Topper as Chief Financial Officer Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now ARQT Media Mentions By Week ARQT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.700.42▲Average Medical News Sentiment ARQT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼224▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OPK News Today SPRY News Today ABVX News Today OCUL News Today IMNM News Today PRAX News Today ETNB News Today TYRA News Today ALXO News Today SAVA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent Nvidia WarningAltimetryElon’s New Device is About to Shock the WorldInvestorPlace"The Biggest Drug Ever" Is ComingBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
